Phase IIb Data Early but Promising
Possible Accelerated Approval Path 'EMERGE[s]' for CDX-011
By Jennifer Boggs
Friday, May 25, 2012
Celldex Therapeutics Inc. is eyeing an accelerated approval pathway after preliminary Phase IIb data showed impressive response rates in three subsets of heavily pretreated breast cancer patients given glycoprotein NMB (GPNMB)-targeting antibody-drug conjugate CDX-011 (glembatumumab vedotin).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.